The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis | BMC Infectious Diseases
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08504-5
From every 1000 H. pylori positive patients, 183 to 206 individuals get GC.
East Asia (China and Japan), South America, Eastern Europe, and Central America are the high-risk,
North and East Africa, North America, Southern Asia, New Zealand, and Australia are the low-risk regions"
#GastricCancer #Helicobacterpylori

BMS signs ADC development deal with Munich-based biotech worth more than $1B —BeiGene's gastric cancer drug succeeds in late-stage trial— FDA green lights Roche's Polivy in first-line DLBCL-- See more on our front page news http://bit.ly/w28kSd #bristolmyerssquibb #drugdevelopment #drugdiscovery #beigene #gastriccancer #dlbcl #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

*From #TumorBoardTuesday archives*

📖Thinking biomarkers but moving to use in #GastricCancer Take a look at @KlempnerSam's October 2021 case presentation & wrap up.

Is there something you'd do different with any updates?
@MPishvaian @JohnEbbenMDPhD

---
RT @TumorBoardTues
1/10 #TumorBoardTuesday
Thursday Case🎀
This week’s case: pt w #GEA not responding to FLOT w dMMR/MSI. Receives 3 doses of pembrolizumab->pCR!

💡Biomarker-based I…
https://twitter.com/TumorBoardTues/status/1453930644094865414

Referenced link: https://phys.org/news/2023-03-antibody-fragment-nanoparticle-therapeutic-eradicates-gastric.html
Discuss on https://discu.eu/q/https://phys.org/news/2023-03-antibody-fragment-nanoparticle-therapeutic-eradicates-gastric.html

Originally posted by Phys.org / @physorg_com: http://nitter.platypush.tech/physorg_com/status/1636403218778411008#m

Antibody fragment-nanoparticle therapeutic eradicates #gastriccancer, shows research @cornell https://onlinelibrary.wiley.com/doi/10.1002/adtp.202200209 https://phys.org/news/2023-03-antibody-fragment-nanoparticle-therapeutic-eradicates-gastric.html

RT @ArndtVogel@twitter.com

🔥Tremelimumab & durvalumab as neoadjuvant treatment for MSI resectable #gastriccancer
@ASCO@twitter.com-GI 2023
👉INFINITY phs-II, 15 pts
👏"Chalabi Plot"... pCR 60%, major response: 80%
👉2pts with disease progression
✅Safe & promising

🐦🔗: https://twitter.com/ArndtVogel/status/1616159888153153536

AZ wins patent fight with Viatris, gains more exclusivity for blockbuster Symbicort — AbbVie leaves PhRMA, BIO: reports —Astellas’ Phase III gastric cancer therapy trial meets primary endpoint -- See more on our front page news http://bit.ly/w28kSd #astrazeneca #patents #Symbicort #BIO #PhRMA #abbvie #astellas #clinicaltrials #gastriccancer #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma

RT @TumorBoardTues
#TumorBoardTuesday

🔬🧬We had a discussion on a new target, Claudin 18.2 in #GastricCancer & #GEJ cancers led by @KlempnerSam

➡️Here’s the Thursday Case 🎀

👉 🆓CME: answer 3 quick ❓
ALL CME 🔗: http://integrityce.com/tbt
CME eval🔗: http://integrityce.com/tbteval

Love the video format..
#TumorBoardTuesday..@JohnEbbenMDPhD@twitter.com

RT @JohnEbbenMDPhD@twitter.com

A huge thanks to @KlempnerSam@twitter.com for an extraordinarily helpful #TumorBoardTuesday discussion looking at Claudin 18.2 as a target in #GEJ & #Gastriccancer.

Looking forward to readouts on IO combinations- hoping this can be a new option for pts w aggressive GI malignancy. https://twitter.com/JohnEbbenMDPhD/status/1601030981615759360

🐦🔗: https://twitter.com/JohnEbbenMDPhD/status/1601268600618201089

RT @JohnEbbenMDPhD@twitter.com

A huge thanks to @KlempnerSam@twitter.com for an extraordinarily helpful #TumorBoardTuesday discussion looking at Claudin 18.2 as a target in #GEJ & #Gastriccancer.

Looking forward to readouts on IO combinations- hoping this can be a new option for pts w aggressive GI malignancy. https://twitter.com/JohnEbbenMDPhD/status/1601030981615759360

🐦🔗: https://twitter.com/JohnEbbenMDPhD/status/1601268600618201089

RT @JohnEbbenMDPhD
A huge thanks to @KlempnerSam for an extraordinarily helpful #TumorBoardTuesday discussion looking at Claudin 18.2 as a target in #GEJ & #Gastriccancer.

Looking forward to readouts on IO combinations- hoping this can be a new option for pts w aggressive GI malignancy. https://twitter.com/JohnEbbenMDPhD/status/1601030981615759360

#TumorBoardTuesday

🔬🧬We had a discussion on a new target, Claudin 18.2 in #GastricCancer & #GEJ cancers led by @KlempnerSam

➡️Here’s the Thursday Case 🎀

👉 🆓CME: answer 3 quick ❓
ALL CME 🔗: http://integrityce.com/tbt
CME eval🔗: http://integrityce.com/tbteval

RT @KlempnerSam
@TumorBoardTues 1/15 #TumorBoardTuesday #GastricCancer #OncTwitter
Here goes

🎬Starting out with an overall poll Q

When a new advanced GC/GEJ patient presents to your clinic, your institution reflexively tests for which of the following?

RT @KlempnerSam
@TumorBoardTues 5/15 #TumorBoardTuesday
✨Claudin18.2 (CLDN18.2)✨

🧑: OK, but is CLDN18.2 rare like NTRK fusions, etc?

🩺: No, prevalence varies by IHC cutoff and IHC assay but…

📍Gastric/GEJ/EAC: ~28-40% of patients are CLDN18.2+ and seen in diffuse and intestinal type #GastricCancer

RT @KlempnerSam
@TumorBoardTues 6/15 #TumorBoardTuesday #GastricCancer
✨Claudin18.2 (CLDN18.2)✨

🧑: 🆒 So does it overlap with other GC/GEJ/EAC biomarkers?

🩺: uuuuuhhhh, we are working on it. With a prevalence of >30% for CLDN18.2+ there is some overlap

RT @KlempnerSam
@TumorBoardTues 8/15 #TumorBoardTuesday #GastricCancer
✨Claudin18.2 (CLDN18.2)✨

🧑: It seems like a tumor-restricted 🎯 target — does that make it amenable to different treatment approaches?

🩺: Yes, several strategies beyond Zolbetuximab are being explored. Here are some examples👇🏽

RT @KlempnerSam
@TumorBoardTues 1/15 #TumorBoardTuesday #GastricCancer #OncTwitter
Here goes

🎬Starting out with an overall poll Q

When a new advanced GC/GEJ patient presents to your clinic, your institution reflexively tests for which of the following?

RT @TumorBoardTues
📢We’re here for #TumorBoardTuesday!!

🥼@KlempnerSam knocks down some pending Q’s about Claudin 18.2 (CLDN 18.2) for upper GI cancer #GastricCancer

👇🏽👇🏽

📱Weigh in your answer
🧾Bring receipts
🙋Ask Q’s
📊check polls
🔁RT
👨🏼‍⚕️tag peers
@MPishvaian @JohnEbbenMDPhD
#MedTwitter https://twitter.com/KlempnerSam/status/1600294104872542209

RT @KlempnerSam
@TumorBoardTues 1/15 #TumorBoardTuesday #GastricCancer #OncTwitter
Here goes

🎬Starting out with an overall poll Q

When a new advanced GC/GEJ patient presents to your clinic, your institution reflexively tests for which of the following?

RT @KlempnerSam
@TumorBoardTues 5/15 #TumorBoardTuesday
✨Claudin18.2 (CLDN18.2)✨

🧑: OK, but is CLDN18.2 rare like NTRK fusions, etc?

🩺: No, prevalence varies by IHC cutoff and IHC assay but…

📍Gastric/GEJ/EAC: ~28-40% of patients are CLDN18.2+ and seen in diffuse and intestinal type #GastricCancer

RT @KlempnerSam
@TumorBoardTues 6/15 #TumorBoardTuesday #GastricCancer
✨Claudin18.2 (CLDN18.2)✨

🧑: 🆒 So does it overlap with other GC/GEJ/EAC biomarkers?

🩺: uuuuuhhhh, we are working on it. With a prevalence of >30% for CLDN18.2+ there is some overlap